Moors & Cabot, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Moors & Cabot, Inc.
- $2.17 Billion
- Q3 2025
A detailed history of Moors & Cabot, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Moors & Cabot, Inc. holds 28,646 shares of RXRX stock, worth $118,594. This represents 0.01% of its overall portfolio holdings.
Number of Shares
28,646
Previous 44,550
35.7%
Holding current value
$118,594
Previous $225,000
38.22%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding RXRX
# of Institutions
360Shares Held
301MCall Options Held
7.71MPut Options Held
4.85M-
Vanguard Group Inc Valley Forge, PA39.8MShares$165 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33.5MShares$139 Million1.15% of portfolio
-
Baillie Gifford & CO24MShares$99.3 Million0.09% of portfolio
-
State Street Corp Boston, MA18.3MShares$75.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$71.7 Million0.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $747M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...